All In Biotech

Drug Trial Radar · NCT05899842

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia. Randomized Open-label Clinical Trial

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de NīmesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.

Conditions

  • Esophageal Achalasia

Interventions

  • Protein pump inhibitor therapy systematicallyDrug

    Lansoprazole 30mg once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of pathological acid reflux between groupsTime frame: Month 6

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • AP-HM

    Marseille, France · Recruiting

  • CHU de Montpellier

    Montpellier, France · Recruiting

  • Clinique mutualiste Beausoleil

    Montpellier, France · Recruiting

  • CHU de Nîmes

    Nîmes, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.